Business Wire

Phelps Brand Launches Penny Oleksiak Collection

Share

Phelps Brand, a global swim brand offering best-in-class, innovative swim products, today announced the launch of a collection inspired by World Champion swimmer Penny Oleksiak. The new collection features special design elements that embody the Phelps Brand global ambassador’s character and personality.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210224005085/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Phelps Brand launches a new collection inspired by World Champion swimmer Penny Oleksiak. (Photo: Business Wire)

“I love being a part of the Phelps Brand team and I jumped at the chance to help create new designs around the products I’m already using,” said Oleksiak. “I want swimmers to feel good and look good while they’re training for their goals.”

The new collection is influenced by Penny’s personality and dedication to increasing participation in the sport, infusing pops of color and unique graphics to invoke feelings of fun and playfulness. The exclusive Penny Oleksiak collection begins to roll out this month with two products available to consumers worldwide so far. The initial product offering includes Xceed goggles that feature unique pink titanium lenses specially designed for training and racing as well as a Sakura swimsuit decorated with delicate Japanese cherry blossoms, known as a symbol for new beginnings.

“This special line was created to capture Penny’s fun, youthful spirit,” said Jessica Fitzsimon, Global Brand Director for Phelps Brand and Aqua Sphere. “We’re excited to redefine our top-of-the-line products with new designs that continue to celebrate the sport of swimming.”

Oleksiak was added to the Phelps Brand roster of global ambassadors in 2020. As part of the Phelps Team, Oleksiak trains and competes utilizing the industry-leading range of products from training equipment to performance swimsuits. A four-time Olympic medalist and six-time World Championship medalist, Oleksiak is a force on Team Canada. As Canada’s youngest Olympic gold medalist, she holds the nation’s record for most Olympic medals at a single summer Games. In her short career she has become known for her exciting come from behind victories, winning four Olympic and six World medals. She currently holds the Olympic Record for the 100 Freestyle.

Made in Italy with Aqua Sphere technology, Phelps Brand develops a technologically advanced range of products from training equipment to performance swimsuits for competitive swimmers under the direction of Michael Phelps and Hall of Fame coach Bob Bowman.

To learn more or to purchase products, go to www.michaelphelps.com.

About PHELPS BRAND

The Phelps Brand offers best-in-class, innovative swim products that are inclusive and accessible to a broad range of swimmers across the competitive swimming lifecycle. Combining Aqua Sphere’s global product design expertise and distribution with Michael Phelps’ and Coach Bob Bowman’s experiences at the highest levels of swim performance, the Phelps Brand features technical swim products leveraging proprietary technologies and performance enhancing designs. For more information or to purchase Phelps Brand products, visit www.michaelphelps.com.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Lindsay Goodson
lgoodson@aqualung.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Stallergenes Greer Expands Venom Immunotherapy Production Capacity With Acquisition of Entomon s.r.l.7.1.2026 12:07:00 EET | Press release

Stallergenes Greer, a global leader in allergy therapeutics, today announced that it has entered into an agreement to acquire Entomon s.r.l., an Italian company specialising in the production of certified stinging-insect venom extracts, notably of the Hymenoptera order, used for the manufacture of diagnostic preparations and Venom Immunotherapy (VIT). The transaction is expected to close by the end of January. Entomon, currently recognised as the only company in Europe capable of extracting pure venom from Hymenoptera insects, produces pharmaceutical-grade insect venom using proprietary techniques (Entomon Capillary Extracted Venom®) for medical use. Through this acquisition, Stallergenes Greer bolsters its venom manufacturing capabilities and supply of raw materials for life-saving VIT treatments, whilst safeguarding patient care continuity. Hymenoptera venom allergy is the most common trigger of severe anaphylaxis in adults1. According to the EAACI guidelines on venom immunotherapy,

ARIS Announces New CEO to Lead Agentic AI-led Strategy7.1.2026 11:00:00 EET | Press release

CEO Appointment ARIS, a global leader in process intelligence and transformation software, today announced the appointment of Guillaume Bacuvier as Chief Executive Officer. Guillaume will lead ARIS through its next phase of growth as a fully standalone company, accelerating its evolution from a market leader in Process Intelligence into a foundational platform for enterprises deploying and governing Agentic AI. Guillaume brings deep international leadership experience across technology, data, and software-enabled businesses, with a proven track record of scaling global platforms and leading complex organisations. After starting as a strategic consultant at Booz Allen Hamilton, Guillaume spent over a decade at Google, rising to Vice President in EMEA where he built and scaled some of Google’s largest data-driven businesses in Europe and held P&L responsibility across multiple countries. In the last decade, Guillaume has served as CEO of multi-continent, data-centric companies including

I Squared Capital Acquires Ramudden Global, a Leader in Traffic Management and Infrastructure Safety7.1.2026 10:00:00 EET | Press release

I Squared Capital, a leading global infrastructure investment manager, today announced that, through its flagship fund, it has agreed to acquire Ramudden Global, from funds advised by Triton Partners (“Triton”), a leading European mid-market sector-specialist investor. Ramudden Global is a leading international provider of traffic management and infrastructure safety services supporting the maintenance and upgrade of essential transport and utility networks. The company operates more than 190 depots across 13 countries in Europe and North America delivering mission-critical services that help to ensure safety, regulatory compliance and continuity of service across road, utility and broader infrastructure works. This investment underscores I Squared Capital’s commitment to investing in essential, regulated, infrastructure businesses that underpin public safety, mobility and economic activity. Ramudden operates in markets where demand is steady and growing and benefits from deep commerci

RoslinCT and BOOST Pharma Announce Strategic Manufacturing Agreement to Advance Cell Therapy for Infants with Osteogenesis Imperfecta7.1.2026 10:00:00 EET | Press release

RoslinCT, a global contract development and manufacturing organization (CDMO) specializing in advanced cell therapies, and BOOST Pharma, a clinical-stage biotechnology company developing first-in-class cell therapies for rare paediatric skeletal diseases, today announced a strategic manufacturing partnership to support the development of BOOST Pharma’s cell therapy, BT-101, for the treatment of infants with Osteogenesis Imperfecta (OI), also known as brittle bone disease. Under the service agreement, BOOST Pharma has transferred its manufacturing process to RoslinCT’s state-of-the-art facilities in Edinburgh, Scotland. The partnership will progress toward GMP manufacturing of starting materials and clinical drug product, supporting Phase III clinical development of BT-101. The therapy is an allogeneic mesenchymal stem cell (MSC) product designed to address the underlying cause of OI at the earliest stages of life. BOOST Pharma was founded on pioneering science originating from Karolins

Daiichi Sankyo and GENESIS Pharma Enter Exclusive Agreement for VANFLYTA ® Commercialization in Central and Eastern Europe7.1.2026 09:30:00 EET | Press release

Daiichi Sankyo (TSE: 4568) and GENESIS Pharma have entered into an exclusive license and supply agreement for the distribution and commercialization of VANFLYTA® (quizartinib) in 13 markets across Central and Eastern Europe for the treatment of adult patients with newly diagnosed FLT3-ITD positive acute myeloid leukemia (AML). Under the terms of the agreement, Daiichi Sankyo will be responsible for the manufacturing and supply of VANFLYTA while GENESIS Pharma will lead medical affairs, market access and commercialization efforts in Bulgaria, Croatia, Cyprus, Czech Republic, Estonia, Hungary, Latvia, Lithuania, Malta, Poland, Romania, Slovakia and Slovenia. Financial terms of the agreement are not being disclosed. VANFLYTA was approved in the EU in November 2023 for the treatment of adult patients with newly diagnosed FLT3-ITD positive AML in combination with standard cytarabine and anthracycline induction and standard cytarabine consolidation chemotherapy, and as maintenance monotherap

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye